NL-OMON56880尚未招募不适用
Prevention of diabetes with a novel butyrate-enriched triglyceride - Preventing Diabetes with Butyrate-Triglyceride
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Male/female
- •Age 20-70 year
- •BMI 28-40 kg/m2 (weight in kg / length in m)
- •One of the following criteria: fasting glucose 5.6-6.9 mmol/l OR postprandial
- •glucose (2h) 7.8-11.1 mmol/l OR HOMA-IR>2.2
排除标准
- •Cardiovascular, pulmonary, metabolic (including diabetes mellitus),
- •gastro-intestinal, liver, kidney or auto-immune disease
- •Malignancy or disease with life expectancy <5 years
- •Substance abuse (drugs, alcohol)
- •Weight change >3kg in past 3 months
- •Pre/pro/antibiotic use past 3 months or during trial
- •Use of medication interfering with study outcomes
- •Streneous physical activity (>3h per week)
- •Diet-restrictions (hypocaloric, vegan, vegetarian)
- •Use of laxatives
研究者
相似试验
招募中
不适用
Butyrate-enriched Triglyceride and Diabetes PreventionType 2 DiabetesObesityPreDiabetesNCT06384313Maastricht University Medical Center48
已完成
不适用
Prevention of future development of diabetes in employees at public schoolsIGTJPRN-UMIN000017662Hokuriku Central Hospital
进行中（未招募）
1 期
PRODIG : Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant periodrenal transplantMedDRA version: 20.0Level: SOCClassification code: 10038359Term: Renal and urinary disorders Class: 18CTIS2024-516272-14-00Centre Hospitalier Regional Universitaire186
已完成
2 期
Anti-platelet therapy for prevention of diabetic nephropathydiabetic nephropathyJPRN-UMIN000007718ational Hospital Organization Headquarters150
已完成
不适用
Research of second line anti-diabetes drug for patients with Type-2 diabetes who received Sitagliptin as first line.Type II diabetes mellitusJPRN-UMIN000014467Fukuoka Tokushukai Medical Center Psychosomatic Medicine132